Skip to content
Screener

Kiniksa Pharmaceuticals International, plc KNSA Q3 2026 earnings

Reported October 27, 2026 · Before market open

Revenue$286.0MBeat by $25.3M
EPS$0.56Beat by $0.19
Revenue estimate$260.7M
EPS estimate$0.37
“Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis. In the third quarter, strong commercial execution led to gains in patient and physician adoption, resulting in revenue of $286.0 million and positioning ARCALYST to achieve blockbuster status this year. Our robust financial position supports continued investment in value creation through ARCALYST, KPL-387, and KPL-1161. We now expect 2026 ARCALYST net sales of between $1.045 and $1.050 billion, up from our previous range of between $980 and $995 million. Additionally, we continue to enroll and dose patients in PASTORALE, the pivotal Phase 3 trial of KPL-387 evaluating once monthly subcutaneous dosing. We expect data in the second half of 2027, with the goal of bringing this important treatment option to patients in the 2028/2029 timeframe. We remain on track to initiate a Phase 1 trial of KPL-1161 by the end of this year.”
Sanj K. Patel

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$286.0M+58.1%
Gross profit$258.2M+60.8%
Operating income$54.2M+126%
Net income$47.3M+157%
EPS (diluted)$0.56+143%

Balance sheet

See full
Cash & equivalents$81.7M-53.3%
Total debt$7.9M-18.9%
Total equity$710.2M+32.7%
Total assets$983.2M+38.0%

Cash flow

See full
Operating cash flow$47.5M+41.2%
CapEx$180.0K-73.2%
Free cash flow$47.4M+43.5%

Valuation & ratios

Valuation

as of 10/27/26
See full
Market cap$5.99B+89.3%
Enterprise value$5.91B+97.6%
P/E54.6×-33.4×
P/S6.3×+1.0×

Profitability

See full
Gross margin90.2%+2.6pp
Operating margin13.8%+7.4pp
Net margin11.6%+5.6pp
FCF margin20.8%+3.8pp

Returns & leverage

See full
Return on equity17.6%+10.2pp
Debt / equity0×0.0×
Current ratio3.9×+0.1×

Segments

By segment

See full
Pharmaceutical$286.0M+58.1%

By product

See full
Collaboration-—

FAQ

When did Kiniksa Pharmaceuticals International, plc report Q3 2026 earnings?
Kiniksa Pharmaceuticals International, plc (KNSA) reported Q3 2026 earnings on October 27, 2026 before market open.
What were Kiniksa Pharmaceuticals International, plc's Q3 2026 revenue and EPS?
Kiniksa Pharmaceuticals International, plc reported revenue of $286.0M and eps of $0.56 for Q3 2026.
Did Kiniksa Pharmaceuticals International, plc beat estimates in Q3 2026?
Revenue beat the consensus estimate of $260.7M by $25.3M. EPS beat the consensus estimate of $0.37 by $0.19.
How did Kiniksa Pharmaceuticals International, plc's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 58.1% from $180.9M a year earlier and eps grew 143.5% from $0.23.
Where can I find Kiniksa Pharmaceuticals International, plc's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001730430-26-000037) and the 10-Q periodic report (0001104659-26-119186) directly on SEC EDGAR. The filing index links above go to sec.gov.